Sime Armoyan Acquires 351,000 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan bought 351,000 shares of the stock in a transaction on Monday, March 25th. The stock was purchased at an average cost of C$5.25 per share, with a total value of C$1,842,750.00.

Sime Armoyan also recently made the following trade(s):

• On Monday, January 22nd, Sime Armoyan sold 28,200 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total transaction of C$162,150.00.
• On Friday, January 19th, Sime Armoyan sold 91,000 shares of Knight Therapeutics stock. The shares were sold at an average price of C$5.75, for a total transaction of C$523,250.00.

Knight Therapeutics Stock Up 3.4 %

Shares of Knight Therapeutics stock opened at C$5.43 on Wednesday. The company has a fifty day moving average price of C$5.47 and a 200 day moving average price of C$5.12. The company has a current ratio of 3.20, a quick ratio of 1.79 and a debt-to-equity ratio of 9.25. Knight Therapeutics Inc. has a twelve month low of C$4.28 and a twelve month high of C$5.75. The stock has a market cap of C$549.35 million, a price-to-earnings ratio of -33.94, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.49.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on GUD shares. Raymond James boosted their price objective on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the company an “outperform” rating in a research note on Wednesday, March 6th. Royal Bank of Canada boosted their price objective on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the company an “outperform” rating in a research note on Friday, March 22nd.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.